About the Company
equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EQ News
Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
Another stock from the same industry, Equillium, Inc. (EQ), has yet to report results for the quarter ended December 2023. This company is expected to post quarterly loss of $0.19 per share in its ...
The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark
Stocks recently featured in the blog include: Janux Therapeutics Inc. JANX, SoundHound Inc. SOUN, Root Inc. ROOT, Equillium, ...
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative, preclinical-stage biopharmaceutical company ...
Top 10 best performing biotech stocks of 2024 so far
Over the past 3 months the biotech space is +30.4% and has only been outperformed by semiconductors, computer processing ...
BioXcel Therapeutics GAAP EPS of -$0.76 beats by $0.15, revenue of $0.38M misses by $0.36M
Q4 GAAP EPS of -$0.76 beats by $0.15. Revenue of $0.38M (+58.3% Y/Y) misses by $0.36M. Cash and cash equivalents totaled $65.2 million on December ...
Loading the latest forecasts...